陈英伟,董建增,马长生

• 1:郑州大学第一附属医院心内科
• 2:首都医科大学附属北京安贞医院心内科

摘要(Abstract)：

目的评估导管消融对阵发性心房颤动(房颤)相关快-慢综合征的疗效。方法连续入选2010年1月至2012年9月在北京安贞医院房颤中心接受导管消融的50例阵发性房颤合并房颤终止后症状性长间歇的患者作为导管消融组,随访观察导管消融的效果。将同期在北京安贞医院因阵发性房颤相关症状性长间歇植入起搏器的61例患者作为起搏器组。比较随访结束时两组患者的窦性心律维持率、心血管原因再住院率等指标。结果导管消融组50例患者术前均具备起搏器植入的适应证,随访(22.3±10.5)个月后发现其中47例(94.0%)患者不再具备起搏器植入的适应证。随访结束时,起搏器组服用抗心律失常药物的比例多于导管消融组(P<0.001),而窦性心律维持率低于导管消融组(起搏器组为21.3%,导管消融组为82.0%,P<0.001);两组心血管原因再住院率比较,差异无统计学意义(导管消融组22.0%,起搏器组24.6%,P=0.954),而起搏器组因快速心律失常发作再住院率高于导管消融组(起搏器组为14.8%,导管消融组为2.0%,P=0.02);两组血栓事件发生率、心力衰竭发生率、死亡率等终点比较,差异均无统计学意义(均为P>0.05)。结论对于阵发性房颤相关快-慢综合征的患者,导管消融的总体效果可能优于起搏器植入,这类患者大多数经导管消融手术成功根治房颤后,可以不用再植入起搏器。

关键词(KeyWords)： 心房颤动;导管消融;起搏器;窦房结功能不全

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈英伟,董建增,马长生

参考文献(References)：

• [1]Epstein AE,DiMarco JP,Ellenbogen KA,et al.ACC/AHA/HRS2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the ACC/AHA/NASPE 2002Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices):developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.Circulation,2008,117:e350-408.
• [2]Kaplan BM,Langendorf R,Lev M,et al.Tachycardia-bradycardia syndrome(so-called"sick sinus syndrome")Pathology,mechanisms and treatment.Am J Cardiol,1973,31:497-508.
• [3]Khaykin Y,Marrouche NF,Martin DO,et al.Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses.J Cardiovasc Electrophysiol,2004,15:784-789.
• [4]Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fi brillation:recommendations for patient selection,procedural techniques,patient management and follow-up,definitions,endpoints,and research trial design:a report of the Heart Rhythm Society(HRS)Task Force on Catheter and Surgical Ablation of Atrial Fibrillation.Developed in partnership with the European Heart Rhythm Association(EHRA),a registered branch of the European Society of Cardiology(ESC)and the European Cardiac Arrhythmia Society(ECAS);and in collaboration with the American College of Cardiology(ACC),American Heart Association(AHA),the Asia Pacifi c Heart Rhythm Society(APHRS),and the Society of Thoracic Surgeons(STS).Endorsed by the governing bodies of the American College of Cardiology Foundation,the American Heart Association,the European Cardiac Arrhythmia Society,the European Heart Rhythm Association,the Society of Thoracic Surgeons,the Asia Pacifi c Heart Rhythm Society,and the Heart Rhythm Society..Heart Rhythm,2012,9:632-696.
• [5]张澍,华伟,黄德嘉,等.植入性心脏起搏器治疗——目前认识和建议(2010年修订版).中华心律失常学杂志,2010,14:245-259.
• [6]Lamas GA,Lee K,Sweeney M,et al.The mode selection trial(MOST)in sinus node dysfunction:design,rationale,and baseline characteristics of the fi rst 1000 patients.Am Heart J,2000,140:541-551.
• [7]Dobrzynski H,Boyett MR,Anderson RH.New insights into pacemaker activity:promoting understanding of sick sinus syndrome.Circulation,2007,115:1921-1932.
• [8]Akoum N,McGann C,Vergara G,et al.Atrial fibrosis quantified using late gadolinium enhancement MRI is associated with sinus node dysfunction requiring pacemaker implant.J Cardiovasc Electrophysiol,2012,23:44-50.
• [9]Alboni P,Baggioni GF,Scarfo S,et al.Role of sinus node artery disease in sick sinus syndrome in inferior wall acute myocardial infarction.Am J Cardiol,1991,67:1180-1184.
• [10]Elvan A,Wylie K,Zipes DP.Pacing-induced chronic atrial fi brillation impairs sinus node function in dogs.Electrophysiological remodeling.Circulation,1996,94:2953-2960.
• [11]Yeh YH,Burstein B,Qi XY,et al.Funny current downregulation and sinus node dysfunction associated with atrial tachyarrhythmia:a molecular basis for tachycardia-bradycardia syndrome.Circulation,2009,119:1576-1585.
• [12]Hadian D,Zipes DP,Olgin JE,et al.Short-term rapid atrial pacing produces electrical remodeling of sinus node function in humans.J Cardiovasc Electrophysiol,2002,13:584-586.
• [13]Chang HY,Lin YJ,Lo LW,et al.Sinus node dysfunction in atrial fibrillation patients:the evidence of regional atrial substrate remodelling.Europace,2013,15:205-211.
• [14]Inada K,Yamane T,Tokutake K,et al.The role of successful catheter ablation in patients with paroxysmal atrial fi brillation and prolonged sinus pauses:outcome during a 5-year follow-up.Europace,2014,16:208-213.
• [15]Nademanee K,Schwab MC,Kosar EM,et al.Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fi brillation.J Am Coll Cardiol,2008,51:843-849.
• [16]Pappone C,Rosanio S,Augello G,et al.Mortality,morbidity,and quality of life after circumferential pulmonary vein ablation for atrial fi brillation:outcomes from a controlled nonrandomized long-term study.J Am Coll Cardiol,2003,42:185-197.
• [17]Themistoclakis S,Corrado A,Marchlinski FE,et al.The risk of thromboembolism and need for oral anticoagulation after successful atrial fi brillation ablation.J Am Coll Cardiol,2010,55:735-743.
• [18]Klug D,Balde M,Pavin D,et al.Risk factors related to infections of implanted pacemakers and cardioverter-defi brillators:results of a large prospective study.Circulation,2007,116:1349-1355.
• [19]Ellenbogen KA,Hellkamp AS,Wilkoff BL,et al.Complications arising after implantation of DDD pacemakers:the MOST experience.Am J Cardiol,2003,92:740-741.
• [20]Wiegand UK,Bode F,Bonnemeier H,et al.Long-term complication rates in ventricular,single lead VDD,and dual chamber pacing.Pacing Clin Electrophysiol,2003,26:1961-1969.